Floatz logo

LYSINE

Neuroendocrine Tumor Grade 1

David BushnellSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Neuroendocrine Tumor Grade 1 cohort.

Asset / SponsorPhaseRating
Everolimus
AC Camargo Cancer Center
Phase 2B
[212pb] vmt-α-net
David Bushnell
Early Phase 1C
ARG
David Bushnell
Early Phase 1C

Same molecule, other indications

LYSINE is also rated in:

Neuroendocrine TumorsDormant
B
Indicative ·
59 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
53 / 100
View asset →
NETsDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →